Ontology highlight
ABSTRACT: Background
The INPULSIS trials revealed that nintedanib reduced the decline in lung function in patients with idiopathic pulmonary fibrosis. We aimed to evaluate the efficacy and safety of nintedanib in Japanese idiopathic pulmonary fibrosis patients in real-world settings.Method
Medical records of idiopathic pulmonary fibrosis patients, who received treatment with nintedanib in five institutions between July 2015 and June 2017, were reviewed. Patients with % forced vital capacity ⩾50% and % predicted diffusing capacity of the lung carbon monoxide ⩾30% were classified as the moderate group and those with more impaired lung functions as the severe group.Result
Among 158 patients analyzed, 132 (84.6%) were classified as the moderate group and 26 (15.4%) as the severe
SUBMITTER: Dobashi M
PROVIDER: S-EPMC8188975 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature